糖耐量受损人群糖尿病发生和心血管疾病预防研究——NAVIGATOR研究结果解读

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance Key implication of NAVIGATOR Trial

NAVIGATOR研究结果已于2010年3月14日在第59届美国心脏病学会年会（ACC）上公布，新英格兰杂志也在网上同步发表。本研究比较了存在心血管危险因素或心血管疾病的糖耐量受损（IGT）人群中，那格列奈以及缬沙坦对于新发糖尿病以及心血管事件共同主要终点的作用。结果显示同样在生活方式干预下，与安慰剂组相比，缬沙坦组新发糖尿病风险降低14％；那格列奈组新发糖尿病及心血管事件没有降低。对此结果，本文将进行深入解读。糖尿病预防，任重而道远。

The results of NAVIGATOR trial were released on March 14, 2010, during the 59th Congress of American College of Cardiology, and published at NEJM. org simultaneously. This trial shows the effect of nateglinide and valsartan in impaired glucose tolerance subjects with high risk factors of cardiovascular or cardiovascular disease outcomes. Under the same intensive life style intervention, compared with placebo, the valsartan shows 14% reduction of incidence of diabetes, but nateglinide has no differences in the key primary outcomes. Based on the results, we will show the key implications. The prevention of diabetes remains a critical public health priority.